Recce Pharmaceuticals (ASX:RCE) to expand EU investor base with FSE listing

  • February 24, 2021 01:02 PM AEDT
  • Team Kalkine
Recce Pharmaceuticals (ASX:RCE) to expand EU investor base with FSE listing

Source: Shutterstock


  • ASX-listed world-leader in synthetic-polymer antibiotics Recce Pharmaceuticals to list its stocks on the FSE.
  • The listing will broaden the investor base and enable access to additional capital markets.
  • Recce Pharmaceuticals has appointed DGWA as its investor and corporate relations advisor in the EU.
Gold MTF non-AMP

A leader in developing anti-Infectives, Recce Pharmaceuticals Ltd (ASX:RCE), has announced the initiation of the application process for listing on the Frankfurt Stock Exchange (FSE).

The Company disclosed that dual listing would lead to increased exposure to a large base of investors. This investor base would include retail and institutional investors across the European Union (EU) via German Trading Exchanges, including Berlin, Frankfurt, Stuttgart, and Tradegate.

© Gepapix |

FSE is the 3rd largest exchange in Europe and 10th largest globally.

Dr John Prendergast, Chairman of Recce Pharmaceuticals, commented:

DO READ: Recce Pharmaceuticals (ASX:RCE) reports positive in-vivo study data against SARS-CoV-2

Investor relations firm DGWA to support intended research programs in the EU

Recce Pharmaceuticals also revealed that it had appointed Deutsche Gesellschaft Für Wertpapieranalyse GMBH (DGWA) as its investor and corporate relations advisor in Europe.

Source: Copyright © 2021 Kalkine Media Pty Ltd.

DGWA will be responsible for the engagement with prospective investors in the German-speaking DACH region, including Austria, Germany, and Switzerland while increasing awareness of the novel synthetic anti-infective compounds of Recce.

Besides, the Company anticipates completing its listing process in near-weeks. Recce Pharma notified that it would provide the market with further updates on its listing process on material developments.

Other latest developments

  • On 16 February 2021, Recce Pharmaceuticals announced that the Company had signed a contract with Fiona Stanley Hospital for a Phase I/II clinical study of RECCE® 327. The trial is to assess the potential of RECCE® 327’s new spray-on, a broad-spectrum antibiotic to treat infections of the topical burn wound.
  • The Company disclosed on 12 February that RECCE® 327 (R327) demonstrated encouraging virucidal effect against novel coronavirus (SARS-CoV2) with a favourable safety profile. RECCE® 327 demonstrated 99.9% efficacy against coronavirus in the confirmatory in-vitro screening assay.

Stock information: On 24 February 2021, RCE shares were trading at A$1.030, down by 1.905% at AEDT 12:54 AM. The Company’s market capitalisation stood at A$182.41 million.

ALSO READ: Are these 3 Healthcare Stocks Geared up for a Strong 2021?



The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK